|Scientific Study Confirms MiMedx dHACM Allograft Promotes Cardiac Repair Following Myocardial Infarction|
The paper entitled "Dehydrated Human Amnion/Chorion Membrane Allograft promotes Cardiac Repair Following Myocardial Infarction," was authored by
Acute myocardial infarction, more commonly known as heart attack, results in irreversible damage or cell death to cardiac tissue and may ultimately lead to heart failure. MiMedx PURION Processed dHACM allografts contain a unique array of regenerative cytokines, growth factors, and extracellular matrix involved in the regulation of tissue healing and modulation of inflammation, suggesting that dHACM grafts may hold promise in treating infarcted cardiac tissue following a heart attack In the scientific study, EpiFix® and AmnioFix® allografts were examined for the ability to prevent cardiac damage or promote healing in an in vivo mouse model of acute left ventricular myocardial infarction.
The highlights of this scientific study, performed at the
"Treatment with dHACM in this animal model improved cardiac repair following myocardial infarction through multiple paracrine effects, including through improved cell survival, enhanced vascularization, and recruitment of autologous stem cells within the infarcted cardiac tissue," noted
"In the study, dHACM allografts appeared to promote cardiac repair after myocardial infarction by reducing the size of fibrotic scaring in the mouse model. Study results such as the stimulated increase in positive stem cells, cell survival and vascularization in infarcted cardiac tissue, suggest that treatment with dHACM may improve cardiac repair through improved blood supply and recruitment of autologous stem cells," concluded Petit.
MiMedx® is an integrated developer, processor and marketer of patent protected and proprietary regenerative biomaterial products and bioimplants processed from human amniotic membrane and other human birth tissues, such as amniotic fluid, umbilical cord and placental collagen, and human skin and bone. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant.
Safe Harbor Statement
This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes. Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the ability of dHACM to attenuate damage or cardiac repair is worthy of very serious consideration in the cardiac community, and the follow-up studies that are planned to be conducted. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that the cardiac care community may not embrace the use of dHACM allografts in the treatment of myocardial infarction as anticipated, follow up studies may not produce the desired conclusions, and the risk factors detailed from time to time in the Company's periodic
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/scientific-study-confirms-mimedx-dhacm-allograft-promotes-cardiac-repair-following-myocardial-infarction-300395816.html
Investor Contact: COCKRELL GROUP, Rich Cockrell, 877-889-1972, email@example.com, cockrellgroup.com; Michael Senken, Phone: (770) 651-9100